{"id":"pravastatin-simvastatin-atorvastatin-rosuvastatin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"1-2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. By reducing hepatic cholesterol production, statins upregulate LDL receptors on hepatocytes, increasing clearance of LDL particles from the bloodstream. This leads to decreased plasma LDL cholesterol and reduced cardiovascular risk.","oneSentence":"These statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:06.813Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of risk of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT06553157","phase":"PHASE1, PHASE2","title":"Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Minia University","startDate":"2024-09-01","conditions":"Solid Tumors, Ototoxicity","enrollment":56},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT06856772","phase":"PHASE4","title":"Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-02-28","conditions":"Cardiovascular Diseases (CVD), Drug Effect, Atherosclerosis Cardiovascular Disease","enrollment":42000},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT06785740","phase":"","title":"Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2024-11-01","conditions":"Ischemic Stroke, TIA","enrollment":300},{"nctId":"NCT06785727","phase":"PHASE4","title":"StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Prof. dr. Nathalie van der Velde","startDate":"2025-02-01","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":612},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT05285085","phase":"","title":"Real World Evidence Study of Statin Use in Brazil","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2021-11-19","conditions":"Cardiovascular Diseases, Myocardial Infarction, Stroke","enrollment":2133900},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT02072161","phase":"PHASE2","title":"Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":133},{"nctId":"NCT03801733","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2018-06-17","conditions":"Drug Interaction Potentiation","enrollment":134},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT01259791","phase":"NA","title":"Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-09","conditions":"Statin Myopathy","enrollment":10},{"nctId":"NCT00850460","phase":"PHASE4","title":"Quality of Life in Patients With Statin-Associated Myopathy","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2009-02","conditions":"Statin Adverse Reaction","enrollment":14},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT00532311","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":411},{"nctId":"NCT02518516","phase":"","title":"High Potency Statins and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":2067639},{"nctId":"NCT02518503","phase":"","title":"High Potency Statins and the Risk of Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-07","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Disease","enrollment":136966},{"nctId":"NCT01972178","phase":"PHASE2","title":"Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia","status":"TERMINATED","sponsor":"Pronova BioPharma","startDate":"2013-11","conditions":"Dyslipidemia","enrollment":113},{"nctId":"NCT02305355","phase":"PHASE4","title":"Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia","status":"COMPLETED","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2, Hypertriglycemia","enrollment":68},{"nctId":"NCT01634906","phase":"NA","title":"Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy","status":"COMPLETED","sponsor":"Sint Franciscus Gasthuis","startDate":"2012-07","conditions":"Hyperlipidemia, Atherosclerosis","enrollment":55},{"nctId":"NCT00718796","phase":"PHASE3","title":"Naturopathic Treatment for the Prevention of Cardiovascular Disease","status":"COMPLETED","sponsor":"The Canadian College of Naturopathic Medicine","startDate":"2008-04","conditions":"Cardiovascular Disease","enrollment":300},{"nctId":"NCT00654537","phase":"PHASE3","title":"STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-04","conditions":"Hypercholesterolemia","enrollment":5625}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin","genericName":"Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin","companyName":"Kuhnil Pharmaceutical Co., Ltd.","companyId":"kuhnil-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}